دورية أكاديمية
أعرض في EDS

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

التفاصيل البيبلوغرافية
العنوان: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, Galamaga, Rob
المصدر: ENT and Skull Base Surgery
بيانات النشر: Barrow - St. Joseph's Scholarly Commons
سنة النشر: 2021
مصطلحات موضوعية: Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Everolimus, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Progression-Free Survival, Protein Kinase Inhibitors, Quinolines, Sunitinib, Survival Analysis
الوصف: BACKGROUND: Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. RESULTS: A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P CONCLUSIONS: Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).
نوع الوثيقة: text
اللغة: unknown
العلاقة: https://scholar.barrowneuro.org/ent-and-skull-base-surgery/23Test
DOI: 10.1056/NEJMoa2035716
الإتاحة: https://doi.org/10.1056/NEJMoa2035716Test
https://scholar.barrowneuro.org/ent-and-skull-base-surgery/23Test
رقم الانضمام: edsbas.9F8C15E
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.9F8C15E
927
3
Academic Journal
academicJournal
926.820373535156
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.9F8C15E&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doi.org/10.1056/NEJMoa2035716# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Motzer%2C+Robert%22">Motzer, Robert</searchLink><br /><searchLink fieldCode="AR" term="%22Alekseev%2C+Boris%22">Alekseev, Boris</searchLink><br /><searchLink fieldCode="AR" term="%22Rha%2C+Sun-Young%22">Rha, Sun-Young</searchLink><br /><searchLink fieldCode="AR" term="%22Porta%2C+Camillo%22">Porta, Camillo</searchLink><br /><searchLink fieldCode="AR" term="%22Eto%2C+Masatoshi%22">Eto, Masatoshi</searchLink><br /><searchLink fieldCode="AR" term="%22Powles%2C+Thomas%22">Powles, Thomas</searchLink><br /><searchLink fieldCode="AR" term="%22Grünwald%2C+Viktor%22">Grünwald, Viktor</searchLink><br /><searchLink fieldCode="AR" term="%22Hutson%2C+Thomas+E%22">Hutson, Thomas E</searchLink><br /><searchLink fieldCode="AR" term="%22Kopyltsov%2C+Evgeny%22">Kopyltsov, Evgeny</searchLink><br /><searchLink fieldCode="AR" term="%22Méndez-Vidal%2C+María+J%22">Méndez-Vidal, María J</searchLink><br /><searchLink fieldCode="AR" term="%22Kozlov%2C+Vadim%22">Kozlov, Vadim</searchLink><br /><searchLink fieldCode="AR" term="%22Alyasova%2C+Anna%22">Alyasova, Anna</searchLink><br /><searchLink fieldCode="AR" term="%22Hong%2C+Sung-Hoo%22">Hong, Sung-Hoo</searchLink><br /><searchLink fieldCode="AR" term="%22Kapoor%2C+Anil%22">Kapoor, Anil</searchLink><br /><searchLink fieldCode="AR" term="%22Alonso+Gordoa%2C+Teresa%22">Alonso Gordoa, Teresa</searchLink><br /><searchLink fieldCode="AR" term="%22Merchan%2C+Jaime+R%22">Merchan, Jaime R</searchLink><br /><searchLink fieldCode="AR" term="%22Winquist%2C+Eric%22">Winquist, Eric</searchLink><br /><searchLink fieldCode="AR" term="%22Maroto%2C+Pablo%22">Maroto, Pablo</searchLink><br /><searchLink fieldCode="AR" term="%22Goh%2C+Jeffrey+C%22">Goh, Jeffrey C</searchLink><br /><searchLink fieldCode="AR" term="%22Kim%2C+Miso%22">Kim, Miso</searchLink><br /><searchLink fieldCode="AR" term="%22Gurney%2C+Howard%22">Gurney, Howard</searchLink><br /><searchLink fieldCode="AR" term="%22Patel%2C+Vijay%22">Patel, Vijay</searchLink><br /><searchLink fieldCode="AR" term="%22Peer%2C+Avivit%22">Peer, Avivit</searchLink><br /><searchLink fieldCode="AR" term="%22Procopio%2C+Giuseppe%22">Procopio, Giuseppe</searchLink><br /><searchLink fieldCode="AR" term="%22Takagi%2C+Toshio%22">Takagi, Toshio</searchLink><br /><searchLink fieldCode="AR" term="%22Melichar%2C+Bohuslav%22">Melichar, Bohuslav</searchLink><br /><searchLink fieldCode="AR" term="%22Rolland%2C+Frederic%22">Rolland, Frederic</searchLink><br /><searchLink fieldCode="AR" term="%22De+Giorgi%2C+Ugo%22">De Giorgi, Ugo</searchLink><br /><searchLink fieldCode="AR" term="%22Wong%2C+Shirley%22">Wong, Shirley</searchLink><br /><searchLink fieldCode="AR" term="%22Bedke%2C+Jens%22">Bedke, Jens</searchLink><br /><searchLink fieldCode="AR" term="%22Schmidinger%2C+Manuela%22">Schmidinger, Manuela</searchLink><br /><searchLink fieldCode="AR" term="%22Dutcus%2C+Corina+E%22">Dutcus, Corina E</searchLink><br /><searchLink fieldCode="AR" term="%22Smith%2C+Alan+D%22">Smith, Alan D</searchLink><br /><searchLink fieldCode="AR" term="%22Dutta%2C+Lea%22">Dutta, Lea</searchLink><br /><searchLink fieldCode="AR" term="%22Mody%2C+Kalgi%22">Mody, Kalgi</searchLink><br /><searchLink fieldCode="AR" term="%22Perini%2C+Rodolfo+F%22">Perini, Rodolfo F</searchLink><br /><searchLink fieldCode="AR" term="%22Xing%2C+Dongyuan%22">Xing, Dongyuan</searchLink><br /><searchLink fieldCode="AR" term="%22Choueiri%2C+Toni+K%22">Choueiri, Toni K</searchLink><br /><searchLink fieldCode="AR" term="%22Galamaga%2C+Rob%22">Galamaga, Rob</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => ENT and Skull Base Surgery )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Barrow - St. Joseph's Scholarly Commons )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%2280+and+over%22">80 and over</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%22">Antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22Monoclonal%22">Monoclonal</searchLink><br /><searchLink fieldCode="DE" term="%22Humanized%22">Humanized</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Agents%22">Antineoplastic Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Combined+Chemotherapy+Protocols%22">Antineoplastic Combined Chemotherapy Protocols</searchLink><br /><searchLink fieldCode="DE" term="%22Carcinoma%22">Carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Renal+Cell%22">Renal Cell</searchLink><br /><searchLink fieldCode="DE" term="%22Everolimus%22">Everolimus</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Kidney+Neoplasms%22">Kidney Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Phenylurea+Compounds%22">Phenylurea Compounds</searchLink><br /><searchLink fieldCode="DE" term="%22Programmed+Cell+Death+1+Receptor%22">Programmed Cell Death 1 Receptor</searchLink><br /><searchLink fieldCode="DE" term="%22Progression-Free+Survival%22">Progression-Free Survival</searchLink><br /><searchLink fieldCode="DE" term="%22Protein+Kinase+Inhibitors%22">Protein Kinase Inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Quinolines%22">Quinolines</searchLink><br /><searchLink fieldCode="DE" term="%22Sunitinib%22">Sunitinib</searchLink><br /><searchLink fieldCode="DE" term="%22Survival+Analysis%22">Survival Analysis</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => BACKGROUND: Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated. RESULTS: A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P CONCLUSIONS: Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.). )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => text )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => unknown )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://scholar.barrowneuro.org/ent-and-skull-base-surgery/23 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1056/NEJMoa2035716 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1056/NEJMoa2035716<br />https://scholar.barrowneuro.org/ent-and-skull-base-surgery/23 )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.9F8C15E )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1056/NEJMoa2035716 ) ) [Languages] => Array ( [0] => Array ( [Text] => unknown ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Adult [Type] => general ) [1] => Array ( [SubjectFull] => Aged [Type] => general ) [2] => Array ( [SubjectFull] => 80 and over [Type] => general ) [3] => Array ( [SubjectFull] => Antibodies [Type] => general ) [4] => Array ( [SubjectFull] => Monoclonal [Type] => general ) [5] => Array ( [SubjectFull] => Humanized [Type] => general ) [6] => Array ( [SubjectFull] => Antineoplastic Agents [Type] => general ) [7] => Array ( [SubjectFull] => Antineoplastic Combined Chemotherapy Protocols [Type] => general ) [8] => Array ( [SubjectFull] => Carcinoma [Type] => general ) [9] => Array ( [SubjectFull] => Renal Cell [Type] => general ) [10] => Array ( [SubjectFull] => Everolimus [Type] => general ) [11] => Array ( [SubjectFull] => Female [Type] => general ) [12] => Array ( [SubjectFull] => Humans [Type] => general ) [13] => Array ( [SubjectFull] => Kidney Neoplasms [Type] => general ) [14] => Array ( [SubjectFull] => Male [Type] => general ) [15] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [16] => Array ( [SubjectFull] => Phenylurea Compounds [Type] => general ) [17] => Array ( [SubjectFull] => Programmed Cell Death 1 Receptor [Type] => general ) [18] => Array ( [SubjectFull] => Progression-Free Survival [Type] => general ) [19] => Array ( [SubjectFull] => Protein Kinase Inhibitors [Type] => general ) [20] => Array ( [SubjectFull] => Quinolines [Type] => general ) [21] => Array ( [SubjectFull] => Sunitinib [Type] => general ) [22] => Array ( [SubjectFull] => Survival Analysis [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Motzer, Robert ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Alekseev, Boris ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rha, Sun-Young ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Porta, Camillo ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Eto, Masatoshi ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Powles, Thomas ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Grünwald, Viktor ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hutson, Thomas E ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kopyltsov, Evgeny ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Méndez-Vidal, María J ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kozlov, Vadim ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Alyasova, Anna ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hong, Sung-Hoo ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kapoor, Anil ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Alonso Gordoa, Teresa ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Merchan, Jaime R ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Winquist, Eric ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Maroto, Pablo ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Goh, Jeffrey C ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kim, Miso ) ) ) [20] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Gurney, Howard ) ) ) [21] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Patel, Vijay ) ) ) [22] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Peer, Avivit ) ) ) [23] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Procopio, Giuseppe ) ) ) [24] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Takagi, Toshio ) ) ) [25] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Melichar, Bohuslav ) ) ) [26] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rolland, Frederic ) ) ) [27] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => De Giorgi, Ugo ) ) ) [28] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Wong, Shirley ) ) ) [29] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bedke, Jens ) ) ) [30] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Schmidinger, Manuela ) ) ) [31] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dutcus, Corina E ) ) ) [32] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Smith, Alan D ) ) ) [33] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dutta, Lea ) ) ) [34] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Mody, Kalgi ) ) ) [35] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Perini, Rodolfo F ) ) ) [36] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Xing, Dongyuan ) ) ) [37] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Choueiri, Toni K ) ) ) [38] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Galamaga, Rob ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2021 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) [1] => Array ( [Type] => issn-locals [Value] => edsbas.oa ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => ENT and Skull Base Surgery [Type] => main ) ) ) ) ) ) )
IllustrationInfo